Cargando…
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
Data are limited regarding the immune status of CD40 ligand (CD40L)–deficient carriers and hematopoietic stem cell transplantation (HSCT) outcomes using them as donors for CD40L-deficient patients. Therefore, we studied the immune profiles of 7 carriers, 4 of whom were HSCT donors for family members...
Autores principales: | Chandrakasan, Shanmuganathan, Chandra, Sharat, Prince, Chengyu, Kobrynski, Lisa J., Lucas, Laura, Patel, Kiran, Walter, Jolan, Buckley, Rebecca H., Meisel, Roland, Ghosh, Sujal, Parikh, Suhag H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631566/ https://www.ncbi.nlm.nih.gov/pubmed/35443026 http://dx.doi.org/10.1182/bloodadvances.2021006905 |
Ejemplares similares
-
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma
por: Byford, Elliot T., et al.
Publicado: (2018) -
CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022) -
Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels
por: Wilk, C. Matthias, et al.
Publicado: (2022) -
CD40-CD40L Interaction in Immunity Against Protozoan Infections
por: Chamekh, Mustapha
Publicado: (2007) -
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020)